CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

Slides:

Advertisements

Similar presentations

Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.

Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Alcohol, Other Drugs, and Health: Current Evidence July–August 2017

The SPRINT Research Group

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

LEADER trial: Primary Outcome

Disclosure Consultations and Honoraria Grant Support

Chronic Kidney Disease in Diabetes

From: Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver DiseaseA Systematic Review.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

The IDEAL Study Reference

Cardiovascular Outcomes Trials with Antihyperglycemic Agents

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

Empagliflozin Empagliflozin is a highly selective inhibitor of the sodium glucose cotransporter 2 (SGLT2) in the kidney Glucose reduction occurs by reducing.

SAVE: Risk of total mortality associated with reduced kidney function

Cardiovascular outcomes

Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs Insulin Glargine U100 in Older Patients (≥65 years) with Type 2 Diabetes.

on behalf of the LEADER Trial Steering Committee and Investigators

366 میلیون نفر در جهان مبتلا به دیابت هستند.

Volume 91, Issue 1, Pages (January 2017)

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Nat. Rev. Cardiol. doi: /nrcardio

Volume 93, Issue 1, Pages (January 2018)

Cardiovascular Disease and CKD: Core Curriculum 2010

Chronic Kidney Disease in Diabetes

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Figure 4 Observational studies on multiple treatment strategies

Nat. Rev. Cardiol. doi: /nrcardio

Volume 76, Issue 10, Pages (November 2009)

Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease Tetsuro Tsujimoto, Hiroshi Kajio

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

Collet JP, et al. Lancet 2009;373:309-17

Methods for guideline development

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management G. B. John Mancini, MD, Alice.

Time to death from diabetes diagnosis for propensity-matched sample adjusted for age, gender, race, and other conditions. Time to death from diabetes diagnosis.

Baseline Characteristics of the Patients – Part I

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Volume 80, Issue 12, Pages (December 2011)

Incidence of contrast-induced nephropathy in patients with CKD, normal kidney function and all patients. Incidence of contrast-induced nephropathy in patients.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Cardiovascular risk in chronic kidney disease

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

Nat. Rev. Nephrol. doi: /nrneph

Emerging Advances in Reducing Renal Complications of T2D

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Correlations among chronic kidney disease (CKD) classification, urinary adiponectin level, eGFR, and ACR. (A) Correlation between CKD classification and.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. The composite analysis of the risk of major adverse cardiovascular events (MACEs) from three cardiovascular outcome trials, expressed as relative.

Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.

Presentation transcript:

SGLT2 inhibitor improves CV outcomes in diabetic patients with chronic kidney disease CANVAS programe subanalyses HR (95%CI): 0.65 (0.41-1.03) 0.71 (0.53-0.95) 0.95 (0.80-1.13) 0.84 (0.62-1.13) MACE: CV death, non-fatal myocardial infarction, or non-fatal stroke SGLT2: Sodium glucose co-transporter 2; CV: cardiovascular; MACE: major adverse CV events; CANVAS: CANagliflozin cardio Vascular Assessment Study Program; eGFR: estimated glomerular filtration rate; T2D: type 2 diabetes; CKD: chronic kidney disease; Neuen et al. Circulation 2018